Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
AbbVie continues to be top of the TV drug ad spenders as its immunology blockbuster Skyrizi dominates this year’s iSpot roundup. After taking the top spot again last month, the Big Pharma is running ...
AbbVie (NYSE:ABBV) announced Wednesday that its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (NASDAQ:AMGN) blockbuster therapy, Otezla, in a Phase 4 head-to-head study for adults ...
Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...
Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...
NORTH CHICAGO, Ill., March 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms ...
Innovent Biologics’ challenger to drugs including Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi has cleared phase 2. The study found the anti-IL-23 monoclonal antibody, which is designed to be ...
"In this study, SKYRIZI showed superior efficacy compared to Cosentyx in helping patients achieve and maintain high levels of skin clearance at week 52," said Michael Severino, M.D., vice chairman and ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback